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Abstract
Background:  The retinoic acid receptor beta 2 (RARβ2) gene modulates proliferation and
survival of cultured human breast cancer cells. Previously we showed that ectopic expression of
RARβ2 in a mouse xenograft model prevented metastasis, even in the absence of the ligand, all-
trans retinoic acid. We investigated both cultured cells and xenograft tumors in order to delineate
the gene expression profiles responsible for an antimetastatic phenotype.
Methods: RNA from MDA-MB-435 human breast cancer cells transduced with RARβ2 or empty
retroviral vector (LXSN) was analyzed using Agilent Human 1A Oligo microarrays. The one
hundred probes with the greatest differential intensity (p < 0.004, jointly) were determined by
selecting the top median log ratios from eight-paired microarrays. Validation of differences in
expression was done using Northern blot analysis and quantitative RT-PCR (qRT-PCR). We
determined expression of selected genes in xenograft tumors.
Results: RARβ2 cells exhibit gene profiles with overrepresentation of genes from Xq28 (p = 2 ×
10-8), a cytogenetic region that contains a large portion of the cancer/testis antigen gene family.
Other functions or factors impacted by the presence of exogenous RARβ2 include mediators of
the immune response and transcriptional regulatory mechanisms. Thirteen of fifteen (87%) of the
genes evaluated in xenograft tumors were consistent with differences we found in the cell cultures
(p = 0.007).
Conclusion:  Antimetastatic RARβ2 signalling, direct or indirect, results in an elevation of
expression for genes such as tumor-cell antigens (CTAG1 and CTAG2), those involved in innate
immune response (e.g., RIG-I/DDX58), and tumor suppressor functions (e.g., TYRP1). Genes
whose expression is diminished by RARβ2 signalling include cell adhesion functions (e.g, CD164)
nutritional or metabolic processes (e.g., FABP6), and the transcription factor, JUN.
Background
It is estimated that approximately 15–25% of women
with node-negative breast cancer will eventually succumb
to the disease due to distant metastases [1]. While
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important and promising anti-hormonal therapies –
tamoxifen and aromatase inhibitors – exist for postmeno-
pausal breast cancer patients with estrogen receptor posi-
tive tumors [2], chemo- and radiation-therapy remain the
major options for all other women with progressive dis-
ease. Elucidating gene expression alterations in metastatic
lesions compared to non-metastatic tumors is compel-
ling, and orthotopic xenograft models provide an avenue
for tackling this challenge. The results of such studies
could lead to rapid translational research and drug discov-
ery [3,4]. Several candidate metastasis-promoting pro-
teins have been identified in differential screening of cell
cultures and primary invasive tumors and these include
ERB2/Her2/neu, VEGF and stromelysin [5]. An exciting
new field of investigation, the search for proteins respon-
sible for inhibition of the metastatic cascade, "metastasis
suppressor" genes, has revealed a set of molecules that
include: NM23 (histidine kinase), KAI1 (a tetraspanin
integral membrane protein that responds to NFκB),
BRMS1 (gap junction function), and MKK4 (mitogen-
activated protein kinase) [4,6,7]. Functions regulated by
metastasis suppressors include transcription, signal trans-
duction, cell adhesion, and inflammation. We have dem-
onstrated that RARβ2, with known tumor suppressor
functions, also confers antimetastatic properties in a
xenograft model of human breast cancer [8].
RARs are members of the nuclear hormone receptor
superfamily, and in conjunction with their heterodimeric
partners, the retinoid X receptors (RXRs), they positively
or negatively regulate (most commonly) genes containing
a direct repeat five (DR5) retinoic acid response element
(RARE) within promoters. Transactivation via these het-
erodimeric partners is generally conferred by physiologi-
cal or pharmacologic levels of retinoid-derived ligands,
including all-trans retinoic acid (AT-RA) and 9-cis-retinoic
acid, for RARs and RXRs, respectively. We and others have
shown that RARβ2 or RARβ4 mRNA is diminished in
most breast cancer cell lines [9,10]. Several laboratories
have also demonstrated loss or diminished expression of
the RARβ2 mRNA in primary breast cancers [11,12]. The
mechanism(s) for diminished RARβ2 expression include
transcriptional repression by epigenetic silencing [13-15].
A truncated, oncogenic RARβ protein (RARβ-prime) is
exclusively expressed in breast cancer cell lines, and the
presence of this isoform likely obstructs tumor suppressor
functions of RARβ2 and RARβ4 protein isoforms [16,17].
RARβ2 activates both tumor suppressor and antimeta-
static programs. In cell cultures in which RARβ2 has been
introduced via a retroviral vector, we found that all breast
cancer cells could be inhibited in their proliferative capac-
ity, even in the absence of the natural ligand, AT-RA.
Moreover, there is a dichotomy in RARβ2-transduced
tumor cells in response to AT-RA: ER-positive cells
undergo apoptosis, while ER-negative cells are further
reduced in their proliferative potential, in comparison to
culture conditions in the absence of AT-RA. In our
xenograft model, we engrafted MDA-MB-435 breast can-
cer cells containing either LXSN-vector or LXSN-RARβ2
into the mammary fat pad (mfp) of nude or SCID mice
[8]. Our model was designed to mimic the treatment of
patients with advanced local disease. After 12–15 weeks,
the mfp-encapsulated, primary tumors were fully resected.
Following an additional 7–11 weeks, the animals were
necropsied and analyzed for multiple parameters, includ-
ing incidence of metastases – the most common sites
being lungs and pleura. The overall incidence of metasta-
sis was 37% (19 of 52 mice) in the vector-control animals
compared to 1.8% (1 of 55 mice) in the RARβ2-expressing
tumor cell implants (p < 0.00001). The one metastatic
lesion from the RARβ2-tumor implant was a micro-metas-
tasis in a nude recipient. SCID recipients showed the high-
est metastatic incidence in the control implants (55%)
compared to none in the animals receiving RARβ2-bear-
ing xenografts.
Very few experiments have been conducted to determine
the downstream factors regulated by ectopic RARβ2
expression. One such study with F9 teratocarcinoma cells,
employing expression microarrays and subtractive hybrid-
ization, found differential expression of transcription fac-
tors, signalling molecules and metabolic enzymes [18].
Moreover, these investigators found that RARβ2 altered
gene expression patterns even in the absence of AT-RA.
Toulouse and colleagues transfected RARβ2 into two lung
cancer cell lines that lacked endogenous RARβ2 expres-
sion [19]. Using the Clontech Atlas human cDNA array,
they identified a significant number of genes involved in
immune responses. It is likely, however, that unique
expression profiles will be found with ectopic RARβ2
expression, depending upon the cell of origin. We used
cultured cells, identical to those in the xenograft studies,
to conduct expression microarray experiments in order to
uncover gene functions or physiologic activities that may
prevent metastasis due to overexpression of RARβ2. Due
to the hierarchical transcriptional regulation by RARβ in
embryogenesis and development, we hypothesized that
multiple regulatory pathways, direct or indirect, could be
mediated by overexpression of RARβ2 in breast cancer
cells.
Methods
Cells and xenograft tumors
MDA-MB-435 human breast cancer cells were transduced
with either the LXSN-vector or LXSN-RARβ2. Plasmid pro-
duction, generation of retroviral vectors, and cell culture
have been described previously [8,20]. For the microar-
rays, cells were grown to confluency in single Corning 150
mm cell culture-treated dishes in breast tumor cell mediaBMC Cancer 2005, 5:140 http://www.biomedcentral.com/1471-2407/5/140
Page 3 of 14
(page number not for citation purposes)
[16]. Two independent culture sets (pairs) were used
among the eight arrays. Cells and RNA for validation
(below) came from the same lineage (within one passage)
as the cells used in the arrays. Tissues were primary,
resected tumors from our previous study [8]. Primary
xenograft tumors were resected and snap frozen in cryop-
reservation media in liquid nitrogen. RNA was extracted
directly from archived primary tumor tissue. Additional
LXSN-vector and LXSN-RARβ2 transductions were per-
formed using the parental MDA-MB-435 cells from a pas-
sage near that of the original transduction and cloning.
These latter cells were grown under selection (500 µg/mL
G-418) on Corning 150 mm cell culture-treated dishes for
10 days when the cells were near confluent, at which time
RNA was collected, as below, for qRT-PCR.
RNA isolation
Total RNA was isolated with Invitrogen's Micro to Midi kit
(Carlsbad, CA) according to the manufacturer's protocol
for cells or tissue, respectively. The purity and integrity of
the RNA was evaluated by measuring the 260/280 nm
optical density ratio and either by use of the Agilent Bio-
analyzer (Agilent Technologies, Palo Alto, CA) or by dena-
turing agarose gel as for Northern blots [10].
RNA labelling, array hybridization, and feature extraction
Five µg of RNA from each transduced cell lineage (LXSN-
vector or LXSN-RARβ2) was labelled using the Agilent Flu-
orescent Linear Amplification kit (Palo Alto, CA).
Labelled RNA was further purified using the Qiagen RNe-
asy Mini kit protocol for liquid samples (Valencia, CA).
Four pairs of labelled cRNA were prepared from two inde-
pendent RNA extractions, hybridized to the Agilent
Human 1A Oligo Array, and washed using the Agilent In
situ Hybridization Kit Plus. cRNA was labelled with Cy5
and Cy3 for "swapped"-labelling for co-hybridizations on
different chips. Hence, every chip had a complimentary
chip with a swapped dye configuration, for a total of eight
chips. Microarrays were scanned in an Agilent DNA
Microarray Scanner and expression data were obtained
using the Agilent Feature Extraction software (version
6.1.1), using defaults for all parameters.
Statistics and analysis
The image file was processed using Agilent's Feature
Extraction software. This Feature Extraction program was
used to identify pixels corresponding to fluorescent signal
(as opposed to background) and to remove pixels with
intensities that met the default criteria for outliers. No
background subtraction was used nor were any of the
available error models used, since the value of these has
not been proven and our replicate data were more highly
correlated without the use of these features. For each iden-
tified area of signal and each of the two dyes, the basic
measure of RNA abundance was taken to be the mean
intensity over pixels in the identified signal area. The log
ratio of the red to green intensities for each signal area (the
mean over approximately 60 pixels per oligonucleotide)
was used for statistical analyses, with all subsequent anal-
yses done using the R statistical software package [21]. The
unit of analysis for the array data was a sample from a sin-
gle cell line with parallel preparations for all samples and
a sample size of eight.
Since the purpose of this study is partially hypothesis for-
mation (as opposed to strict hypothesis testing), we
elected a priori to examine the 100 most extreme median
log ratios (over the eight cell culture arrays) for large dif-
ferences between the treatments as well as biological pat-
terns that could lead to more explicit hypothesis testing in
future experiments using primary xenograft tumors. The
median was chosen as the summary measure of expres-
sion across the eight arrays (for each oligonucleotide)
because the median has been shown to have better per-
formance than mean-based statistics, such as the t-statistic
or the SAM statistic, in identifying spiked-in RNAs using
small sample sizes [22]. This method of analysis is also
similar to that suggested by Breitling et al. [23], with both
biological and statistical considerations used to choose
the analysis method, except that especially low or high
ranks are given less weight in the current method than in
the rank product method suggested therein. Before
median log ratios were calculated, data from each array
were normalized separately using the R function lowess,
with a window size of approximately 360 points. The joint
significance level (p-value) for finding 100 median log
ratios as extreme or more extreme than observed was
determined using the permutation test under the null
hypothesis of no differential expression in any of the
genes between the two groups, as in Pollard and van der
Laan, comparing the 100th absolute value order statistic to
its permutation reference distribution [24].
Standard binomial probabilities were used to determine
the significance of concordance between quantitative real-
time PCR (qRT-PCR) results [see below] using RNA from
cultures and tissue and the apparent over-representation
of Xq28 genes in the top 100 list.
Finally, since an unusually large number of top 100 ratios
corresponded to genes on Xq28, we searched the sequence
of Xq28 (positions Xq28:146,767,469–154,804,778 from
human assembly, hg17, using Known Gene data down-
loaded from the UCSC Genome Browser [25], for matches
to the conserved portions of the RARβ DR5 DNA binding
element (βRARE) using the UNIX utility "agrep" [26]. Six
βRARE sequences were found within the 89 listed "Known
Genes" (exons, introns, plus 1000 upstream and down-
stream base pairs) on Xq28. In addition, the genomic
regions for three other non Xq28 genes of interestBMC Cancer 2005, 5:140 http://www.biomedcentral.com/1471-2407/5/140
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(ZADH1, ZNF387, FABP6), including the leading and
ending 100 base pairs, were searched for RAREs.
Validation: quantitative RT-PCR, northern blot and 
western blot
Total RNA from cells and tissue was treated with 1 U of
RNase-free deoxyribonuclease 1 (DNase 1) (Ambion,
Austin, TX) per µg of RNA to eliminate genomic DNA con-
tamination. DNase 1 was inactivated with the addition of
2.5 mM EDTA (pH 8.0), followed by 10 minutes at 65°C.
cDNA synthesis and PCR analysis were performed using
the Invitrogen SuperScript III Platinum Two-Step qRT-
PCR Kit with SYBR Green. Quantitative gene expression
was detected using the LightCycler (Roche Molecular Bio-
chemicals, Mannheim, Germany). The Invitrogen proto-
col includes a step using uracil DNA glycosylase and dUTP
to prevent amplification of carryover PCR products.
All primers (Supplemental Table 1) were designed with
Primer3 [27] using sequences contained in the 60-mer oli-
gonucleotide probes found on the Agilent Human 1A
Oligo Array. The arrays contain probes synthesized in situ
on glass slides by phosphoramidite chemistry. Probes
were designed with a 3' bias from collective database
sources representing 17,086 genes [28]. Primers were syn-
thesized by Qiagen [aka Operon] (Valencia, CA). qRT-
PCR reactions for all samples were carried out in triplicate
for each gene. In some cases, additional qRT-PCR was per-
formed with independent RNA samples, as indicated in
Tables 1 and 5. Genomic DNA from MDA-MB-435 paren-
tal cells was used to generate a standard curve, as this con-
sistently gave values for slope, error and regression
coefficient recommended for optimal results by Roche
and based on calculations by Pfaffl [29]. All samples were
normalized with respect to the constitutively expressed
large ribosomal phosphoprotein P0 (RPLP0, aka 36B4)
gene. The normalized data were then used to generate a
differential expression ratio to compare to the expression
microarray data. In cases where we were unable to con-
firm the expression differential obtained from the micro-
array analyses, we interrogated Map Viewer [30] or
AceView [31] to determine if the 60-mer overlapped
Table 1: Top twenty ranked genes
Gene Symbol 
(Probe)
Name †Fold change 
(qRT-PCR)
Rank Function/Other information
LSAMP Limbic system associated membrane protein -3.2 (-3.1) 1 Immunoglobulin superfamily member; cell adhesion
SLC38A2 Solute carrier family 38 -2.2 (-2.1) 2 Amino acid transporter A2, regulated by growth 
factors & hormones
CTAG1 Cancer/testis antigen 1 2.2 *(1.6, 1.5) 3 (see also Table 2)
MGC2780 Hypothetical protein -2.2 (-5.5) 4 Unknown
§PCDH11Y Proto-cadherin on the Y -2.1 (-1.9) 5 Cell adhesion X chromosome homologue
PCSK4 Convertase; subtilisin/kexin 4 -2.0 (-1.6) 6 Cleave pro-hormones and pro-growth factors
ZADH1 Zinc-binding alcohol dehydrogenase domain 
containing protein
1.9 *(1.3, 1.2) 7 Alcohol dehydrogenase; possible retinoid 
metabolism
CD164 Cluster designation protein 164 -1.9 (-1.5) 8 Sialomucin, AKA, MGC-24
SFTPA2 Surfactant pulmonary associated protein 1.8 NC 9 Calcium dependent signalling innate immune 
response
FLJ23577 Hypothetical Kruppel-like protein -1.8 NC 10 unknown
SR-BP1, OPRS1 Sterol binding protein Opoid receptor sigma -1.7 NC 11 Sterol isomerase, ergosterol biosynthesis
FABP6 Fatty acid binding protein 6 -1.7 (-6.6) 12 Bile acid binding;
OR52P1 Olfactory receptor 52 pseudogene 1.7 NC 13 Pseudogene
CSTA Cystatin A -1.7 (-2.3) 14 Cysteine proteinase inhibitor
NPDC1 Neural differentiation & control protein 1.7 *(1.5, 1.3) 15 Inhibits proliferation
NXT2, P15-2 Nuclear transport factor 2-like export factor 1.7 NC 16 Exports RNA from nucleus
SECTM1 Secreted and transmembrane protein 1 -1.6 (-2.8) 17 Signal transduction activity with the NF-κB cascade
HKE2 HLA class II region KE2 gene 1.6 NC 18 Protein folding
NNMT Nicotinamide N-methyltransferase -1.6 (-4.6) 19 Methylates pyridines; biotransformation of drugs; 
enhanced in cancer cells
ZNF387, ST18 Zinc finger protein 387; breast cancer tumor 
suppressor
1.6 (2.7) 20 Transcription (see also Table 4)
† "Fold change," top number is the relative expression of RARβ2 transduced cells/empty vector control cells from Agilent arrays. The number in 
parentheses is the relative expression of the same cells from qRT-PCR analysis, normalized by respective qRT-PCR RPLP0 expression.
NC = not confirmed. In all cases, these genes have known isoform(s) [with exception OR52P1, which is a pseudogene] that overlap(s) the 60-mer 
probes on the arrays, which could account for the discrepancy between array finding and qRT-PCR.
* two qRT-PCRs (each in triplicate) of independent RNA samples
§shares near identical homology to homologue on X chromosomeBMC Cancer 2005, 5:140 http://www.biomedcentral.com/1471-2407/5/140
Page 5 of 14
(page number not for citation purposes)
mRNA isoforms (e.g., splice variants) known for the gene
of interest.
Northern blot methods are as described [32]. Northern
probe production for SPP1 and CTAG1 is as follows: the
1384 bp SPP1 probe was generated from vector control
cells using Qiagen's One step RT-PCR mix (with primers:
Fwd CATCACCTGTGCCATACCAG and Rev CCGT-
GGGAAAACAAATAAGC). The 463 bp CTAG1 probe was
generated from both RARβ2 and vector control cells using
Qiagen's One step RT-PCR mix (with primers: Fwd
CTTCAGGGCTGAATGGATG and Rev AACAAACATG-
TAAGCCGTCCT). An example of the difference in the
level of RARβ2 mRNA in the transduced cells is shown in
Figure 1A.
Two independent samples of the RARβ2- and vector-trans-
duced cells were analyzed for SPP1/osteopontin using
methods from Tuck et al. [33]. Briefly, 5 × 105 cells were
plated on Corning 100 mm cell culture-treated dishes in
breast cancer cell media [32] and incubated for 18 hours.
Cells were then grown in 3 ml of serum-free breast cancer
cell media for 24 hours. The media was centrifuged briefly
to eliminate cellular debris, and then concentrated in an
Expression of RARβ2 and CTAG1 by Northern analysis Figure 1
Expression of RARβ2 and CTAG1 by Northern analysis. Northern analysis of RARβ2 (A) and CTAG1 (B) in RARβ2-
transduced MDA-MB-435 cells compared to vector-control cells. Using total RNA used in the arrays, Northern blots were 
probed with 32P-dCTP labelled RARβ2 or CTAG1 cDNA. The RARβ2 probe consists of ~1.2 kb KpnI-BamH1 digest fragment 
of pSG RARβ2 ([75], from Pierre Chambon). The CTAG1 probe was generated from a 463 bp reverse transcriptase PCR 
product that encompasses the Agilent 60-mer. Blots were sequentially probed with a cDNA for RPLP0 (36B4) as a loading and 
transfer control. Quantitation of relative transcript levels was normalized to RPLP0 by phosphorimaging using exposure levels 
within the linear range of detection, avoiding saturation. The RARβ2 mRNA includes elements transcribed from the retroviral 
vector [8].
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Amicon Ultra-4 (Millipore, Billerica, MA) with a 10 kDa
cut off at 1500 rpm for 1.5 hrs, resulting in a final volume
of ~60 µL each. The adherent cells were trypsinized and
counted using a hemocytometer. Cells were lysed, using a
mild lysis buffer (50 mM Tris-HCI pH 8, 300 mM NaCI,10
mM MgCI2,1 mM EDTA, 25 mM β-glycerophosphate,
0.5% lgepal-CA 630 [Sigma I3021]) [34] with a protease
inhibitor cocktail (Roche, Mannheim, Germany). Protein
from ~3 × 105 cell equivalents of both media and cell
lysates were separated, along with recombinant SPP1 (gift
from Dr. CM Giachelli), with SDS-PAGE and then blotted
to PVDF membrane (BioRad, Hercules, CA). The mem-
brane was probed using a 1:3,500 dilution of a goat anti-
SPP1 polyclonal antibody (gift from Dr. CM Giachelli)
followed by a horseradish peroxidase-conjugated rabbit
anti-goat antibody at 1:20,000 (Pierce, Rockland, IL). The
blot was visualized by chemiluminescent detection
(Pierce).
Results & discussion
Differential expression level changes comparing cells with 
metastatic potential to RARβ2-overexpressing cells
RARβ2 is overexpressed in MDA-MB-435 cells transduced
with a retroviral vector containing the full-length RARβ2
cDNA (Figure 1A). We hypothesized that the antimeta-
static functions of RARβ2 were transcriptionally medi-
ated, independent of excess or therapeutic concentrations
of ligand, AT-RA, as it has been demonstrated that RARβ2
can modulate gene expression even in the absence of
exogenous ligand [18,35].
Of the top 100 candidates (Additional File 2: Supplemen-
tal Table 2), which includes rank, fold change (RARβ2/
vector), chromosome localization, and URL links to
GeneCards), eighty-six comprised unique gene candi-
dates, the remaining being duplicate probes on the arrays.
The p-value for finding 100 median ratios this extreme or
more extreme was p = 0.004. Fifty-three of the eighty-six
unique probes (62%) indicated induced expression in
RARβ2-transduced cells.
The relative ratios in expression levels between the
RARβ2-transduced cells/vector control cells and the mag-
nitude of the differences were confirmed in fourteen of
the top twenty ranked median candidates (70%) by qRT-
PCR (Table 1). In addition, CTAG1 expression differences
were confirmed by northern blot analysis (Figure 1B). For
two of the fourteen confirmed candidates, FABP6 and
NNMT, the magnitude detected by qRT-PCR was greater
than that detected with the expression microarrays. Over-
all, there was excellent concordance as to whether the
gene candidate was induced or diminished between the
array and qRT-PCR results.
Five genes were not confirmed (NC) by qRT-PCR. How-
ever, for each of these candidates, we hypothesize that
there is potential overlap of an mRNA isoform with the
Agilent 60-mer probe, as determined in Map Viewer or
AceView for each gene. The remaining single probe,
OR52P1, is a pseudogene, which could not be validated.
The top twenty genes obtained from the statistical analysis
and subsequent validation provide an interesting window
into the antimetastatic cellular functions mediated by
RARβ2 in MDA-MB-435 cells. Three candidates, all
reduced in RARβ2 cells, are implicated in cell adhesive
properties of tumors (LSAMP [rank 1], PCDH11Y [rank
5], and CD164 [rank 8]). CD164 is a sialomucin, and in
general, both transmembrane and secreted mucins can
regulate growth factor receptor activity. Furthermore, can-
cer cells may subvert the normal role of the extensively
post-translationally modified mucins or sialomucins in
order to sense the environment and regulate metastasis
[36]. Another category of genes, all with diminished
expression in RARβ2 cells, are implicated in nutritional
regulation or sensing, and hormone metabolism:
SLC38A2 [rank 2], PCSK4 [rank 6], SR-BP1 [rank 11], and
FABP6 [rank 12]. Two other genes of note in the top
twenty ranked candidates that are elevated in RARβ2 cells
are NPDC1 [rank 15] and ZNF387/ST18 [rank 20]. Little
has been reported on these genes, but both are likely tran-
scriptional regulatory molecules. NPDC1 has been associ-
ated with cessation of proliferation in the nervous system
[37], and ZNF387/ST18 is hypothesized to be a tumor
suppressor gene in breast cancer [38].
In order to rule out a clonal influence on the antimetasatic
phenotype of RARβ2, we also performed qRT-PCR on
mixed clones from our original transduction in order to
look at a more heterogeneous culture. The pools consisted
of equal numbers of cells from five RARβ2 clones and
three vector-control clones. RNA extracted from these
mixed populations underwent qRT-PCR, using primers
from the top seven ranked genes. As shown in Additional
File 3: Supplemental Table 3, all seven genes were vali-
dated. Additionally, we introduced LXSN-control and
LXSN-RARβ2 vectors into MDA-MD-435 cells, and fol-
lowing a ten-day selection in G-418, collected RNA from
the newly transduced cell populations. Also shown in
Supplemental Table 3, six of the seven top genes were
validated.
Genes in the cancer/testis antigen family localized to Xq28 
are elevated in RARβ2 overexpressing cells
Eleven of the top 100 (87 unique) genes reside on the X
chromosome, including CTAG1 [rank 3] (Supplemental
Table 2 & Table 2). Of these, eight map to Xq28, the most
telomeric cytogenetic long-arm band (Table 2). Given that
there are seventy-five Xq28 genes on the array, p = 2 × 10-BMC Cancer 2005, 5:140 http://www.biomedcentral.com/1471-2407/5/140
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8 for finding eight Xq28 genes among the most differen-
tially expressed 86 unique genes, using an a priori null
hypothesis of no preference for Xq28 genes. Five of the
eight probes or genes belong to the large cancer/testis (C/
T) antigen gene family, which include CTAG1, CTAG2,
LOC389903, MAGEA2, and TRAG3. The array experi-
ments suggested that the C/T genes are induced either
directly or indirectly by the presence of RARβ2 compared
to the empty vector cells. We originally evaluated and val-
idated CTAG1 by Northern blot analysis (Figure 1B) and
secondarily by qRT-PCR, both of which showed an
approximately two-fold or greater expression in RARβ2-
transduced cells/vector control cells. The mRNAs for two
C/T genes, LOC389903 and TRAG3, share significant
sequence overlap within their respective 60-mer probes,
which may account for our inability to confirm expression
rations for these genes by qRT-PCR. Similarly, the
MAGEA2 60-mer probe differs by 1 or 2 nucleotides com-
pared to MAGEA3, MAGEA6, or MAGEA12.
C/T genes consist of over forty families, and their expres-
sion may not be limited to germ line cells as a small subset
are expressed in somatic cells, particularly the pancreas
[39,40]. As discussed by Scanlon et al., many of these pro-
teins are expressed in breast cancers [40]. Recently, Montel
et al. performed expression profiling using two well-char-
acterized clones derived from MDA-MB-435 cells, one
that metastasized in xenograft experiments, and the other
that failed to metastasize. They found that a number of C/
T genes (including CTAG1, CTAG2, a colon cancer antigen
16, and MAGEA1) were elevated in the clone that did not
metastasize [41]. Theoretically, an adaptive immune
response may be responsible for biologic effect; however,
members of the C/T family may have as yet unknown
functions, independent of tumor antigenicity. For exam-
ple, MAGE-11 was recently shown to be a co-activator of
the androgen receptor in androgen dependent tissue. This
latter discovery was conducted with yeast two-hybrid
interactions and functional analysis [42]. Cronwright and
colleagues found that the C/T genes are expressed in mes-
enchymal stem cells but are down-regulated following dif-
ferentiation [43]. This latter observation supports the
interesting hypothesis that cancer cells are stem cell
derivatives.
Additional genes on Xq28
Three additional genes on Xq28 with apparent up-regula-
tion by RARβ2 were confirmed by qRT-PCR (Table 2).
ARHGAP4 is a GTPase-activating protein that may modu-
late stress fiber organization and function [44]. RPL10 is a
60S ribosomal protein that may possess other functions,
including the ability to bind cYES kinase and affect SH3-
mediated signal transduction cascades, resulting in tumor
suppressor functionality [45]. Finally, SSR4, signal
sequence receptor delta 4, was also elevated in RARβ2
cells. SSR4 encodes a protein subunit for a complex
involved in protein secretion [OMIM:300090].
Is Xq28 enriched with beta retinoic acid response 
elements?
Six potential RAR binding elements were found during the
search of the genomic coding sequences, including 1000
base pairs upstream and downstream from the start and
stop codons, corresponding to known genes on Xq28. In
this analysis, we simply searched for previously reported
RARβ response elements [46], since this has the potential
to provide additional information regarding regulatory
pathways. Additional File 4: Supplemental Table 4 lists
the sequences found and their locations. In comparison,
no known RAREs were found in the regions of ZADH1,
Table 2: Gene cluster on Xq28
Gene Symbol 
(Probe)
Name †Fold change 
(qRT-PCR)
Rank Function/Other information
ARHGAP4 Rho-GAP GTPase 1.4 (2.2) 44 Possible inhibitory role on stress fiber 
organization and microtubules
§CTAG1 Cancer/testis antigen 1 2.2 (1.6) 3
§CTAG2 Cancer/testis antigen 2 1.3 (1.6) 93
§ *LOC389903 Cancer antigen 1.3 (NC) 75
§ **MAGEA2 Cancer antigen 1.3 (NC) 73
RPL10 Ribosomal protein 1.6 (1.4) 22 Tumor suppressor
SSR4 Signal sequence receptor/translocon associated 
protein delta
1.4 (1.2) 52 Type I receptor in endoplasmic reticulum/
intracellular protein transport
§ *TRAG3 Tumor antigen 1.3 (NC) 77
† "Fold change," top number is the relative expression of RARβ2 transduced cells/empty vector control cells from Agilent arrays. The number in 
parentheses is the relative expression of the same cells from qRT-PCR analysis, normalized by respective qRT-PCR RPLP0 expression.
NC = differential expression was not confirmed by qRT-PCR
§ Genes in the cancer/testis antigen superfamily
* Shares significant overlapping sequence within their respective 60 mer probes, differing by 2–3 nucleotides
** MAGEA2 60 mer probe shares significant sequence identity with MAGEA-3, -6, and -12 (differs by 1–2 nucleotides)BMC Cancer 2005, 5:140 http://www.biomedcentral.com/1471-2407/5/140
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ZNF387, nor FABP6, none of which are Xq28 genes,
though this does not rule out the possibility that novel
RAREs or more distant RAREs contribute to the expression
of these genes. These are intriguing results, given the large
number of Xq28 genes with differential expression in this
experiment. More research is needed to determine the sig-
nificance of these results, both statistically (after deter-
mining the appropriate control for comparison of the
number of elements found) and biologically (by testing of
authentic RARβ2 binding within the larger context of the
sites). We note that the genes in Supplemental Table 4
were all on the array but were not in top 100 ranked genes
(Supplemental Table 2). One caveat to consider is that
even if the putative RAREs are nearest to the noted genes,
the RARE sites could act as distant transcriptional regula-
tory elements, as is the case for the HOX gene cluster,
where RARE activation may occur at distances from 6 to
more than 20 kilo bases [47]. In addition, RAREs may be
found in 3' regions of genes [48]. If future expression pro-
filing experiments using tumors should reveal more genes
at Xq28, we could test as a control the possibility of retro-
viral integration at this site by fluorescence in situ hybrid-
ization and molecular mapping. Despite the preliminary
nature of these results, they provide a basis for further
research by us and others as well as demonstrate a poten-
tially simple and powerful auxiliary analysis to array
experiments that makes use of the growing amount of
knowledge of consensus sequences.
Candidate genes involved in immune response and 
interferon signalling
As introduced above with the C/T genes on Xq28, a high
proportion of the most extreme 100 median-log genes are
associated with immune function. Table 3 lists additional
immune function candidates. Of the nine genes in Table
3, five are known to be regulated through interferon or are
involved in interferon signalling: IFI27 [rank 81], IFIT1
[rank 47], IFITM1 [rank 28], RIG-I [rank 79], and USP18
[rank 35].
Two genes, IFIT1 and IFITM1, are elevated in RARβ2 cells
compared to control cells. IFIT1, which is induced by
interferon alpha in response to viral infection, contains
ten tetratricopeptide repeats, and these repeats are
hypothesized to confer stability to the protein [49].
IFITM1 is induced by both alpha and gamma interferons.
Based on the protein sequence, IFITM1 is likely an integral
membrane protein, and exogenous expression in COS
cells confers an antiproliferative, non-migrating pheno-
type [50]. A recent study of chronic myelocytic leukaemia
patients determined that expression of IFITM1 in neoplas-
tic cells predicted improved survival [51].
Two other interferon regulated genes are diminished in
RARβ2 cells compared to control cells, IFI27 and USP18/
UPB43. In one study, ~50% of human breast cancers
expressed elevated IFI27 RNA, which was inversely corre-
lated with estrogen receptor status [52]. Moreover, retin-
oids have been shown to suppress IFI27's expression [53].
Interferon signalling pathways are multi-nodal and
involve molecules such as AKT, PCK, various STATs and
NFκB [54]. The results of our expression microarray stud-
ies suggest that exogenous RARβ2 may modulate inter-
feron signalling in MDA-MB-435 cells, leading to
enhanced immune surveillance 'in the host.' Expression
profiles indicated that RIG-I/DDX58 [rank 79] was ele-
vated in RARβ2-transduced cells. This observation was
confirmed with qRT-PCR for both the cell cultures (Table
3) and tumor tissue (Table 5). RIG-I is a retinoic acid
inducible gene that encodes an RNA helicase/adaptor pro-
Table 3: Immune response and interferon signalling
Gene Symbol 
(Probe)
Function/family †Fold change 
(qRT-PCR)
Rank Function/Other information
APP Amyloid precursor protein 1.6 (ND) 21 Proinflammatory
HLA-DRB1 Histocompatability complex, class II, DR beta 1 -1.3 (ND) 89 Signal transduction; antigen processing
IFI27 Interferon (IFN)-alpha inducible Protein 27 -1.3 (-1.9) 81 Integral membrane protein; unknown function
IFIT1 IFN-induced protein with tetratricopeptide 
repeats
1.4 (1.3) 47 Transmembrane protein; Interferon, retinoic 
acid inducible
IFITM1 IFN-induced transmembrane protein 1 1.5 (2.9) 28 Growth inhibition
PTMA/TMSA Prothymosin A -1.4 (ND) 53 Innate immunity; nuclear; associated with 
proliferation
RIG-I/DDX58 Retinoic acid inducible gene I/DEAD box 58 1.3 (1.7) 79 IFN signalling; RNA helicase
TRA1/GP96 Tumor rejection antigen 1 1.3 (NC) 98 Glycoprotein; stress response
USP18/UBP 43 Ubiquitin specific protease 18 -1.5 (-1.6) 35 Protease/ubiquitinase regulated by IFN
† "Fold change," top number is the relative expression of RARβ2 transduced cells/empty vector control cells from Agilent arrays. The number in 
parentheses is the relative expression of the same cells from qRT-PCR analysis, normalized by respective qRT-PCR RPLP0 expression.
ND = not done
NC = differential expression was not confirmed by qRT-PCR, and this gene has mRNA isoform that overlaps the 60-mer probeBMC Cancer 2005, 5:140 http://www.biomedcentral.com/1471-2407/5/140
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tein that is critical in sensing virus and propagating inter-
feron gamma innate responses [55].
Candidate genes involved in transcription regulation
RARs are requisite transcription factors for a vast array of
biological functions, such as embryogenesis, develop-
ment, homeostasis, vision, and the immune system [56].
There are likely thousands of genes regulated directly
through RAR transcriptional activation through canonical
binding elements in gene promoters. One of the more
well-characterized systems in development is the inter-
play between RARs and HOX gene expression [57]. Table
4 lists candidate genes that may have a transcriptional
function in either permitting or abrogating metastasis.
HOXB7, which has higher expression in the control cells,
may have a role in neoplasia, as it was shown to block dif-
Table 4: Transcriptional regulation: global and targeted
Gene Symbol 
(Probe)
Name †Fold change 
(qRT-PCR)
Rank Function/Other information
ANC 2H01/ZNF639/
ZASC1
Zinc finger protein 639 1.3 (ND) 76 Kruppel domain
CITED4 CPB/p300-binding protein & interacting 4 1.3 (ND) 74 Transcriptional coactivator
FJL23577 Hypothetical, Kruppel-like protein -1.8 (NC) 10 Unknown
HIPK2 Homeodomain-p53-interacting protein -1.4 (ND) 51 Homeodomain interacting protein kinase 2
HOXB7 Homeobox gene B7 (ANTP family) -1.4 (-1.2) 38 Inhibits differentiation
*JUN cJUN -1.3 (-1.5) 90 AP1 complex
KIAA115 SIT4 phosphatase-associated protein-like -1.3 (ND) 82 Cyclin/G1 transcription
MGC15737/TCEAL3 Transcription elongation factor A-like 3 1.3 (ND) 100 Transcriptional elongation
ZNF387, ST18 Zinc finger protein 387; breast cancer 
suppressor of tumorigenicity
1.6 (2.7) 20 Transcription/Tumor suppressor (see also 
Table 2)
†"Fold change," top number is the relative expression of RARβ2 transduced cells/empty vector control cells from Agilent arrays. The number in 
parentheses is the relative expression of the same cells from qRT-PCR analysis, normalized by respective qRT-PCR RPLP0 expression
ND = not done
NC = not confirmed, has at least two isoforms that overlap the 60-mer probe
* "cross-talks" with RARs
Table 5: Comparison of expression: xenograft tumors and cultured cells
Gene symbol (Rank) Array fold change Cell fold change †Tissue fold change
ARGAP4 (44) 1.4 2.2 1.1
CA14 (86) -1.3 -1.9 -1.2
CTAG1 (3) 2.2 1.6 2.2
CTAG2 (93) 1.3 1.6 1.2
IFI27 (81) -1.3 -1.9 -1.4
‡IFIT1 (47) 1.4 1.3 -1.2
‡IFITM1 (28) 1.5 2.9 -1.5
JUN (90) -l.3 -1.5 -1.2
NDRG1 (42) 1.4 4.5 2.9
RPL10 (22) 1.6 1.4 1.2
RIG-I (79) 1.3 1.7 1.1
RNF28 (37) -1.5 *-2.2/-1.7 -1.4
SSR4 (52) 1.4 1.2 1.6
ST18 (20) 1.6 2.7 1.8
USP18 (35) -1.5 -1.6 -1.3
†Fold change for tissue was determined by dividing the normalized (to RPLP0) qRT-PCR value of two tumors that contained exogenous RARβ2 by 
the normalized value of two tumors that contained the empty vector.
‡Map Viewer or AceView indicate that there are overlapping mRNA isoforms with the 60 mer probe.
*two qRT-PCRs (each in triplicate) of independent RNA samplesBMC Cancer 2005, 5:140 http://www.biomedcentral.com/1471-2407/5/140
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ferentiation of myelocytic cells [58]. ZNF387/ST18 (see
also Table 1) likely exhibits tumor suppressor function of
as yet unknown mechanism.
The finding of a potential down-regulation of the cJUN
mRNA is very intriguing, as RARs and members of the AP1
family such as JUN have major antagonistic interactions
and both gene families are master regulators of many
physiologic functions. JUN and AP1-associated family
members are key transcription factors that block the anti-
proliferative functions of p53, p21, and p16 [59]. The
mechanisms of cross-repression by RARs [60], and partic-
ularly by RARβ2 [61], which inhibit JUN and AP1 activity,
include sequestering of co-activators and blockage of
signalling pathways that recruit transcriptional activators
such as CBP [62]. We demonstrated metastasis suppres-
sion in the absence of pharmacologic ligand, AT-RA [8].
Moreover, it has been independently demonstrated that
RARβ can abrogate AP1 activity and inhibit anchorage
independent colony formation of RARβ-stably transfected
MDA-MB-231 breast cancer cells [63]. Two other gene
candidates apparently regulated by the transcription fac-
tor NFκB, SECTM1 [Table 1, Rank 17] and SLC20A1
[Rank 29], are also elevated in RARβ2 cells, and NFκB sig-
nalling is likely an important pathway mediating metasta-
sis suppressor functions, including RIG-I [7,64].
SPP1/Osteopontin expression and a validation dilemma Figure 2
SPP1/Osteopontin expression and a validation dilemma. SPP1 expression comparison of RNA and protein. A. North-
ern blot analysis. Eight µg of whole cell total RNA extracts were probed with a 1384 bp fragment of SPP1 (see methods) or 
800 bp, Pst1 fragment of RPLP0 (36B4). Phosphorimaging was used for detection and quantitation. B. Western immunoblot 
analysis. Two independent preparations of each clonal cell line were used. Three mL of serum free-media from 3 × 105 cell 
equivalents was immunoblotted, using a goat anti-SPP1/osteopontin polyclonal antibody (antibody and recombinant protein 
were a gift from Dr. CM Giachelli) and a secondary rabbit anti-goat antibody (Pierce).
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A cautionary note concerning unexpected findings in gene 
array validation
Ten of the top 100 gene candidates were SPP1 (osteopon-
tin), and there were ten independent SPP1 probes of the
same sequence on the Agilent arrays (Supplemental Table
2). The statistical results indicated that SPP1/osteopontin
was elevated (~1.4 fold) in RARβ2-transduced cells. We
carefully investigated this unexpected finding, as SPP1/
osteopontin may be a key player in promoting metastasis
[65] or breast cancer progression [66]. Moreover, SPP1/
osteopontin may be a critical protein component in breast
cancer's ability to metastasize to bone [67]. Northern blot
analysis also suggested that SPP1/osteopontin was mar-
ginally elevated at the steady state level in RARβ2 cells
(Figure 2A). qRT-PCR findings also showed an increase in
the level of SPP1/osteopontin message comparing
RARβ2- to vector control-cells. Finally, we analyzed the
media of the vector control and RARβ2 cells by western
blot for possible differences in protein levels. Interest-
ingly, we detected both slightly higher protein levels plus
a higher molecular weight form of SPP1/osteopontin pro-
tein in the vector control cells. There was no evidence for
SPP1 protein in the western blot of cellular lysates, only
from the concentrated media. (Figure 2B). SPP1/oste-
opontin can be post-translationally modified via a vast
variety of moieties, including N- or O-linked glycosyla-
tion, phosphorylation, cross-linking with other proteins,
deamidation, oxidation and carbamylation. Recently
mass spectrometry experiments demonstrated that SPP1
has over thirty potential phosphorylation residues
Model of antimetastatic functions modulated by RARβ2 Figure 3
Model of antimetastatic functions modulated by RARβ2. Expression of RARβ2 in metastatic breast cancer cells confers 
multiple antimetastatic properties, including induction of cancer antigens, tumor suppressors, and genes involved in interferon 
signalling. Other gene activities are suppressed through RARβ2 action: AP1, cell adhesion, and nutrient processes. All gene 
activities in this diagram have been confirmed by cell culture qRT-PCR. Gene names in italics (red), have also been confirmed 
using randomly selected xenograft primary tumors, comparing two pairs of vector control- and RARβ2-resected tumors.
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[68,69]. Whatever the sum of post-translational changes,
the modified protein is likely a better substrate for
possible interactions with fibronectin that may confer
enhanced cellular migration.
Comparison of candidates derived from cell culture with 
primary xenograft tumors
We evaluated expression of selected genes of interest in
two pairs of xenograft tumors from nude mice. We chose
the gene candidates using the following criteria: 1) they
had been validated by qRT-PCR in the cell cultures; and 2)
they sampled the full rank range (Table 5). One candidate,
CA14 [carbonic anhydrase 14, rank 86], with evidence for
RARβ2-mediated diminished expression, is elevated in a
variety of cancers, particularly hypoxic tumors [70].
Another candidate, NDRG1 [N-Myc down-stream regu-
lated gene 1, rank 42], is regulated by the PTEN protein
and may control metastasis in colon, prostate, and breast
cancers [71,72]. Although the precise function(s) for
NDRG1 has not been elucidated, Kim et al. demonstrated
p53-dependent microtubule check point function for the
protein in breast cancer cells [73]. Stein et al. found that
NDRG1 was transcriptionally regulated by p53 and is nec-
essary, but not sufficient, for p53 modulated apoptosis
[74]. Thirteen of fifteen selected genes are consistent
between cell cultures and the randomly selected tumors
(p = 0.007). Thus our hypothesis testing, using cell lines
from the xenograft studies, suggests that RARβ2-manifest
anti-metastasis functions preexist in the transduced cells.
Conclusion
Our expression profiling experiments revealed both
potential activated and repressed cellular activities in
response to overexpression of RARβ2 (Figure 3). RARβ2
induces expression of several members of the C/T antigen
family found on Xq28 as well as interferon signalling
genes (Tables 2 and 3), suggesting that therapeutic modu-
lation of RARβ2 in tumor cells may enhance endogenous
immunity or potentially be additive to therapeutic immu-
nomodulation. Our profiles indicate that RARβ2 induces
a number of tumor suppressor functions (NDRG1,
RPL10, and ST18) and known metastasis suppressors
(NDRG1 and TYRP1). We find that the expression of a
number of genes involved in cell adhesion (LSAMP,
PCDH11Y, and CD64); nutrient availability (FABP6,
SLC38A2, PCSK4, SRPB1); and transcription/AP1 activity
(HOXB7 and JUN) are repressed in RARβ2 cells. Our find-
ings suggest new arenas of complimentary or synergistic
pathways in the regulation of metastasis.
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